Recombinant therapeutic antibodies and proteins market

Recombinant Therapeutic Antibodies and Proteins Market, by Drug Class (Plasma Protein, Growth factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Enzyme, Coagulation Factors, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, trends, and Forecast to 2026

Request Free Sample

Jul 2018
CMI1981
160 Pages
Excel & Pdf
Biotechnology

Summary

Recombinant Therapeutic Antibodies and Proteins Market– A Novel Approach to Treat Rare and Chronic Diseases

Therapeutic proteins are engineered in the laboratory for pharmaceutical use, including non-covalent binders. These proteins are highly effective and serve as modernized treatment for rare as well as chronic diseases. Protein therapeutics offer custom-made treatment approach by supporting a specifically targeted therapeutic process by compensating the deficiency of an essential protein. Recombinant proteins have gained significant traction for therapeutic applications and the number of proteins either launched or approved into clinical trials has continually increased over the past two decades. According to the National Center for Biotechnology Information (NCBI) data of 2017, the U.S. Food and Drug Administration (FDA) approved over 140 recombinant therapeutic proteins for human use and several hundred are currently in development. Majority of these proteins are recombinant monoclonal antibodies.

The global recombinant therapeutic antibodies and proteins market size was valued at US$ 91.2 billion in 2017, and is expected to witness a robust CAGR of 12.2% over the forecast period (2018 – 2026).

Figure 1. Global Recombinant Therapeutic Antibodies and Proteins Market Share (%), By Drug Class

Source: Coherent Market Insights Analysis (2018)

Advancements in recombinant therapeutic drugs are expected to bolster the recombinant therapeutic antibodies and proteins market growth

Integration of novel approaches and strategies to modify protein drug products is an important aspect. Advancements in recombinant protein technologies have allowed drug manufacturers and developers to adjust required functional characteristics of proteins of interest while maintaining product efficacy and safety.

Various recombinant technologies are currently in use to increase the half-life, functionality, and targeting of novel therapeutic protein drugs and increase product purity and volume. For instance, protein conjugation and derivatization methods, including albumin-fusion15, PEGylation and Fc-fusion are currently being used to extend a drug’s circulating half-life.

Monoclonal antibodies (mAbs) are most commonly used recombinant therapeutic products. The production of most monoclonal antibody products is easily amenable to effective platform-based approaches as antibodies are highly specific and the risk of unexpected safety issues in human clinical trials of mAb products is less as compared to other types of therapeutic products. The constant evaluation of monoclonal antibody drugs in new and expanded clinical indications results in constant demand for products in clinical studies ensuing increased sales in newly approved indications.

Figure 2. Recombinant Therapeutic Antibodies and Proteins Market (US$ Bn), By Region, 2017

Source: Coherent Market Insights Analysis (2018)

Increasing government support for novel drug development is expected to augment the market growth

Governments are supporting research and development of novel products due to rapid advancements in biomedical science and technology to address unmet medical needs. In 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed to provide the FDA with the capability to establish breakthrough therapy designation (BTD), a new program within the Expedited Programs for Serious Conditions. It was designed to be available for drugs designed to treat a serious condition and that have been shown to exhibit initial clinical evidence of significant improvement over existing treatments.

Moreover, increasing number of rare diseases significantly impacting public health is expected to drive growth of the recombinant therapeutic antibodies and proteins market size. According to National institute of Health (NIH) 2018 report, an estimated 7,000 different disorders collectively affect about 10% of the U.S. population, mainly young children and many lack effective treatments. In order to encourage the development of drugs that specifically address unmet medical needs, in 2013, an orphan designation was given for drugs used for the treatment of less than 200,000 patients in the U.S.

However, government regulations are stringent for production and approval of recombinant therapeutic drugs in order to ensure that these products are effective and safe.

Major players operating in the global recombinant therapeutic antibodies and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck & Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.

Table of Content

Table of Contents

Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

Market Purview

Report Description

Market Definition and Scope

Executive Summary

Market Snippet, By Drug Class
Market Snippet, By Application
Market Snippet, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities

Global Recombinant Therapeutic Antibodies and Proteins Market, By Drug Class, 2016 – 2026, (US$ Million)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends

Plasma Protein

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Growth Factors

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Fusion Proteins

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Monoclonal Antibodies

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Hormones

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Enzyme

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Coagulation Factors

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Others

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Global Recombinant Therapeutic Antibodies and Proteins Market, Application, 2016 – 2026, (US$ Million)

Introduction

Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017–2026
Segment Trends

Oncology

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Hematology

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Immunology

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Endocrinology

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Infectious Disease

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Cardiovascular Disease

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Others

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)

Global Recombinant Therapeutic Antibodies and Proteins Market, By Region, 2016 – 2026, (US$ Million)

Introduction

Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2026
Regional Trends

North America

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

U.S.
Canada

Latin America

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

Brazil
Mexico
Argentina
Rest of Latin America

Europe

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe

Asia Pacific

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific

Middle East

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

GCC
Israel
Rest of Middle East

Africa

Market Size and Forecast, By Drug Class, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2016 – 2026, (US$ Million)

South Africa
Central Africa
North Africa

Competitive Landscape

Heat Map Analysis
Company Profiles

Abbott*

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Amgen Inc.

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Biogen Inc.

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Eli Lilly and Company

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

F. Hoffmann-La Roche

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Johnson and Johnson

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Merck & Co.

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Novo Nordisk

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Pfizer Inc.

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Sanofi S.A.

Company Overview
Product Portfolio
Key Highlights
Financial Overview
Market Strategy

Analyst Views

Section

References
Research Methodology
About us and Sales Contact

*Browse 22 market data tables and 27 figures on "Recombinant Therapeutic Antibodies and Proteins Market - Global forecast to 2026”.

N/A

- Frequently Asked Questions -

What are the growth estimates for recombinant therapeutic antibodies and proteins market till 2026?

The global recombinant therapeutic antibodies and proteins market is estimated to surpass US$ 250 Billion by 2026

Which are the prominent recombinant therapeutic antibodies and proteins market players across the globe?

Which segment based on drug class, accounted for the highest demand in the recombinant therapeutic antibodies and proteins market?

Among drug class, monoclonal antibodies segment held dominant position in the recombinant therapeutic antibodies and proteins market, in 2017 due to increasing applications of mAbs in therapeutics

What are the key factors driving growth of the recombinant therapeutic antibodies and proteins market?

Advancements in recombinant therapeutic drugs is one of the major factors that is expected to propel growth of the market over the forecast period.

What is the Compound Annual Growth Rate (CAGR) of the recombinant therapeutic antibodies and proteins market for next 8 years?

The global recombinant therapeutic antibodies and proteins market is estimated to exhibit a CAGR of 12.2% over the forecast period

Which region is dominating the recombinant therapeutic antibodies and proteins market growth?

Among regions, North America holds a dominant position in the global recombinant therapeutic antibodies and proteins market, owing to increasing R&D expenditure and increasing product approvals.